Ricerca clinica: studi con farmaci sperimentali

AVE625 Sanofi A double blind placebo-controlled study of the activity of AVE 1625 at dosis of 10 mg and 40 mg for 12 weeks in patients with mild to moderate Alzheimer?s diseases. STUDY  ACT10019

AVA102675 – Glaxo – A 52-week open-label extension study of the long-term safety and efficacy of rosiglitazone extended-release (RSG XR) as adjunctive therapy to acetylcholinesterase inhibitors in subjects with mild-to-moderate Alzheimer’s disease (RFLECT-4)

ENA713 Exelon Patch Rivastigmine CENA 713D2340 – Novartis – A 48-week, multicenter, double-blind, parallel-group evaluation of the comparative efficacy, safety and tolerability of Exelon 10 and 15 cm2 patch in patients with Alzheimer’s disease showing cognitive decline during an initial open-label treatment phase.

Studio multicentrico, a dosaggio differenziato, randomizzato, in doppio cieco, a gruppi paralleli, controllato verso placebo di RO5313534 quale aggiunta al trattamento con donepezil in pazienti affetti da malattia di Alzheimer con sintomatologia da lieve a moderata. Roche, prot. WN22018

Effect of passive immunization on the progression of Alzheimer’s disease: LY2062430 versus placebo. Eli Lilly, prot. H8A-MC-LZAN

Effect of LY450139, a g-secretase inhibitor, on the progression of Alzheimer’s disease as compared with placebo. Eli Lilly, prot. H6L-MC-LFBC

Randomised, double blind, parallel-group, placebo-controlled, fixed-dose study of Lu AE58054 in patients with moderate Alzheimer’s disease treated with donepezil. Lundbeck, prot. 12936A

AZ3110866,Glaxo, prot. AZ3110866. A fixed dose study of SB-742457 versus placebo when added to existing donepezil treatment in subjects with mild-to-moderate Alzheimer’s disease.

A randomised controlled trial to assess the efficacy of a food for special medical purposes (FSMP) in patients with mild Alzheimer’s disease – Souvenir II trial – Danone, prot. Alz.1.C/D

A phase 2a study to evaluate the effect of rilapladib (SB-659032) on biomarkers related to the pathogenesis and progression of Alzheimer’s disese (LPZ114458)

A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effect on cognitive performance, safety, and tolerability of SAR110894D at the doses of 0.5 mg, 2 mg, amd 5mg/die for 24 weeks in patients with mild to moderate Alzheimer’s disease

A randomized, placebo-controlled, multicenter study to evaluate the safety and tolerability of multiple dose regiments of CHF 5074 (200, 400, 600 mg/day for up to 12 weeks) and to explore the effects on potential markers of clinical efficacy in patients with mild cognitive impairment (CCD-1014-PR-0053)